Who Generates More Revenue? Dr. Reddy's Laboratories Limited or BioMarin Pharmaceutical Inc.

Dr. Reddy's Dominates Revenue Over BioMarin

__timestamp	BioMarin Pharmaceutical Inc.	Dr. Reddy's Laboratories Limited
Wednesday, January 1, 2014	751040000	132170000000
Thursday, January 1, 2015	889895000	148189000000
Friday, January 1, 2016	1116854000	154708000000
Sunday, January 1, 2017	1313646000	140809000000
Monday, January 1, 2018	1491212000	142028000000
Tuesday, January 1, 2019	1704048000	153851000000
Wednesday, January 1, 2020	1860455000	174600000000
Friday, January 1, 2021	1846275000	189722000000
Saturday, January 1, 2022	2096039000	214391000000
Sunday, January 1, 2023	2419226000	245879000000
Monday, January 1, 2024		279164000000

Unlocking the unknown

Revenue Showdown: Dr. Reddy's vs. BioMarin

In the competitive landscape of pharmaceuticals, revenue generation is a key indicator of a company's market strength. Over the past decade, Dr. Reddy's Laboratories Limited has consistently outperformed BioMarin Pharmaceutical Inc. in terms of revenue. From 2014 to 2023, Dr. Reddy's revenue surged by approximately 86%, reaching a peak in 2023, while BioMarin's revenue grew by about 222% over the same period. Despite BioMarin's impressive growth rate, Dr. Reddy's revenue in 2023 was over 100 times greater than BioMarin's. This stark contrast highlights Dr. Reddy's dominant position in the market. However, it's worth noting that data for 2024 is incomplete, leaving room for potential shifts in the coming years. As the pharmaceutical industry continues to evolve, these two giants will undoubtedly play pivotal roles in shaping its future.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025